The pharma division of Bayer has quietly become the company’s most reliable source of good news. The latest development arrived this week when Japanese regulators granted marketing approval for Sevabertinib, the company’s targeted therapy for HER2-mutant non-small cell lung cancer (NSCLC). Sold under the brand name Hyrnuo in Japan, the drug has secured a clearance that goes beyond what the company achieved in other major markets.
Unlike the accelerated approvals Sevabertinib received from the US FDA in November 2025 and from China’s NMPA early in 2026 — both of which were limited to patients who had already undergone systemic therapy — the Japanese authorization carries no such restriction. Physicians in Japan can now prescribe the drug as a first-line treatment, a distinction that meaningfully expands the addressable patient population. For a company leaning heavily on its oncology portfolio to offset the patent cliff facing older blockbuster products, that breadth matters.
A Second Asian Regulatory Win
The Japan approval is not an isolated event. Bayer has also made headway in China, where regulators have accepted the company’s filing for Aflibercept 8 mg, an ophthalmology candidate designed to treat macular edema caused by retinal vein occlusion. The acceptance marks the formal start of the Chinese review process — a step short of approval, but a signal that the company’s pipeline is gaining momentum across Asia.
That momentum comes at a time when investors are parsing every piece of regulatory and legal news for clues about the stock’s trajectory. The share price has been largely indifferent to the recent approvals, however. After closing Tuesday at €49.28, up 1.8 percent on the day, the stock has barely budged on a weekly basis, adding just 0.08 percent. The longer-term picture is more compelling: the shares have climbed 33 percent since the start of the year and remain 8.5 percent below the 52-week high of €53.86 touched on July 3.
The Numbers Behind the Narrative
The operational foundation for these pipeline advances rests on the half-year results Bayer published in early August. Second-quarter group revenue rose 2.2 percent on a currency- and portfolio-adjusted basis to €10.872 billion, while EBITDA before special items advanced 1.9 percent to €2.144 billion. Net income swung from a loss of €199 million in the year-earlier quarter to a profit of €219 million, though core EPS of €0.95 came in 16.7 percent below the prior-year figure.
Should investors sell immediately? Or is it worth buying Bayer?
Management also trimmed its full-year guidance for net financial debt to between €29 billion and €30 billion, reflecting the €3.0 billion capital injection from Apollo-managed funds announced earlier. That cash infusion has helped reshape the balance-sheet narrative, even as the agricultural division continues to underperform relative to pharma.
The September Date That Overshadows Everything
For all the progress in the lab and the clinic, the dominant overhang remains the glyphosate litigation in the United States. The Missouri Circuit Court has pushed back the fairness hearing for the multibillion-dollar class settlement from its originally scheduled August 19 date to September 14. The settlement itself — valued at up to $7.25 billion — was agreed in February, with payments structured to stretch over a maximum of 21 years. But until the court gives its final blessing, the legal uncertainty that has weighed on the stock for years will persist.
Technical indicators suggest the shares are not overheated despite the recent run. The relative strength index sits at 57.8, and the stock trades 4.2 percent above its 50-day moving average — neither signal points to stretched conditions. The company’s market capitalization stands at €47.20 billion, a figure that appears to price in both the pharma pipeline’s promise and the residual legal risk.
There is also a peripheral distraction: Bayer weighed in on the German cartel office’s non-binding assessment of the so-called 50+1 rule in professional football, a matter that touches the company through its sports division but carries little weight for capital-market valuation.
For investors, the calculus is straightforward. The pharma division keeps delivering regulatory wins that strengthen the long-term growth story, while the September 14 court date in Missouri remains the key short-term catalyst. Until then, the stock is likely to keep trading on the tension between those two forces — a pipeline that is expanding and a legal overhang that refuses to fully recede.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from August 26 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 26.
Bayer: Buy or sell? Read more here...
